clinical research strategies in msa gregor k. wenning md phd msc division of neurobiology department...
TRANSCRIPT
Clinical Research Strategies in MSA
Gregor K. Wenning MD PhD MSCDivision of NeurobiologyDepartment of Neurology & NeurosurgeryMedical University [email protected]
JiePieAward, BrusselsOctober 2nd, 2014
EMSA Sites 10 / 2014
24 Study Sites in 12 EU Countries + Israel
www.emsa-sg.org
EMSA Registry
Köllensperger et al., 2010
• 436 consecutive patients recruited
• Mean age at disease onset: 57.8 years
• Baseline disease duration: 5.8 years
• 68.2% MSA-P
• Symptomatic autonomic failure in 99%• Urinary incontinence in 83%• Orthostatic dysregulation in 75%
• Parkinsonism in 87%
• Ataxia in 63%
EMSA Registry
Köllensperger et al., 2010
Pharmacological Treatment
• Autonomic failure
• Orthostatic symptoms treated in 27%
• Midodrine – 69%
• Fludrocortisone – 25%
• Urinary dysfunction treated in 19%
• Tolterodine – 52%
• Oxybutinin – 45%
• Parkinsonism
• L-Dopa – 73% (beneficial response in 38%)
• DA – 29%
• MAO-B inihbitors – 11%
EMSA Registry
Köllensperger et al., 2010
Under-Treatment
Trial considerations
• Progression of motor impairment
• Progression of non-motor impairment
• Progression of global disability
• Worsening of Hr-QoL
• Progression of surrogate markers
Male : female 13 : 21 Age (yrs) 64.0 ± 7.1 Age at symptom onset (yrs)
59.9 ± 6.6
Disease duration at baseline (yrs)
4.1 ± 3.1
Follow-up duration (months)
11.8 ± 1.4
UPDRS III progression in MSA-P
H&Y
Mean UPDRS-III change: 10.8 (95%CI 8.5 – 13.1)
H&Y 3 (n=22): 13.1 (95%CI 10.9 – 15.3)
H&Y 4 (n=12): 6.5 (95%CI 2.1 – 10.9)
Seppi K et al, 2005
Annual UPDRS-III increase in PD: 1.5% ranging from 0.6-4.5
Olanow 1995; Louis 1999; Goetz 2000; Jankovic 2001
Male : female 13 : 21 Age (yrs) 64.0 ± 7.1 Age at symptom onset (yrs)
59.9 ± 6.6
Disease duration at baseline (yrs)
4.1 ± 3.1
Follow-up duration (months)
11.8 ± 1.4
H&Y
Male : female 13 : 21 Age (yrs) 64.0 ± 7.1 Age at symptom onset (yrs)
59.9 ± 6.6
Disease duration at baseline (yrs)
4.1 ± 3.1
Follow-up duration (months)
11.8 ± 1.4
H&Y
EMSA – Natural History
Wenning et al. 2013
Baseline
• Minimal Data Set
• Rating Scales (UMSARS, H&Y, S&E, EQ5D, ...)
• Red Flag Screen
6-Months
• Minimal Data Set
• Rating Scales (UMSARS, H&Y, S&E, EQ5D, ...)
• Red Flag Screen
12-Months
• Minimal Data Set
• Rating Scales (UMSARS, H&Y, S&E, EQ5D, ...)
• Red Flag Screen
18-Months
• Minimal Data Set
• Rating Scales (UMSARS, H&Y, S&E, EQ5D, ...)
• Red Flag Screen
24-Months
• Minimal Data Set
• Rating Scales (UMSARS, H&Y, S&E, EQ5D, ...)
• Red Flag Screen
EMSA - Natural HistoryN 141Diagnostic certainty
Possible (%) 19.9Probable (%) 77.3
SexFemale (%) 44.0Male (%) 56.0
AgeStudy entry (years, mean ± SD) 62.1 ± 7.7Disease-onset (years, mean ± SD) 56.2 ± 8.4Disease duration baseline (years, mean ± SD) 5.5 ± 3.8
Global disability scale (mean ± SD) 2.3 ± 0.7Schwab & England ADL (mean ± SD) 4.9 ± 2.2Hoehn & Yahr Parkinson (mean ± SD) 3.7 ± 1.0Symptomatic autonomic dysfunction (%) 96.5Parkinsonism (%) 90.8
Beneficial L-Dopa Response(%) 31.2Response duration (years, mean ± SD) 3.5 ± 2.7
Ataxia (%) 71.6
Wenning et al., 2013
EMSA – Natural History
Wenning et al., 2013
EMSA – Natural History
Wenning et al., 2013
0%
10%
20%
30%
40%
50%
60%
6-Months 12-Months 18-Months 24-Months
ADL MEPer Protocol Analysis
UMSARS Progression Clinical Milestones
EMSA supported sample sizecalculation for trials
Wenning et al., 2013
30% effect size 159 patients per group (80% power)
30% effect size 186 patients per group (80% power)
Factors associated with rapid progression of motor impairment in MSA
• Lower baseline impairment Seppi et al, 2005
• Absent L-Dopa response Wenning et al, 2013
• Short disease duration Seppi et al, 2005; Geser et al, 2006; Wenning et al, 2013
• Cerebellar features at baseline Geser et al, 2006
Trial considerations
• Progression of motor impairment
• Progression of non-motor impairment
• Progression of global disability
• Worsening of Hr-QoL
• Progression of surrogate markers
Progression of self perceived dysautonomia in MSA
6 months
Trial considerations
• Progression of motor impairment
• Progression of non-motor impairment
• Progression of global disability
• Worsening of Hr-QoL
• Progression of surrogate markers
H&Y progression in pathologically confirmed parkinsonian disordes
Median H&Y III latency in MSA: 43 months (6 – 100)Median H&Y IV latency in MSA: 56 months (6 - 118)
Mueller et al., 2000
N = 18; 13; 11; 15; 24
PD
MSADLBPSP
0
20
40
60
80
100
Cas
es (
%)
PD CBD DLB MSA PSP
Diagnosis
HY I
HY II
HY III
H&Y I
H&Y II
H&Y III
PD CBD DLB MSA PSP
Ca
se
s (
%)
H&Y stages within 1 year of motor onset H&Y progression
N = 81
PROGRESSION IN MSADisability-milestones
MEDIAN TIME TO years
Walking aids 3 – 5
Wheelchair 5 – 6
Bedridden state 8
Death 9.0 – 9.5
· approx. 50-60% of patients wheelchair-bound at 5 years· Survival rate at 5 years approx. 84% · Survival rate at 10 years approx. 40%
Wenning et al. 1994, N=100; Watanabe et al. 2002, N=230
Trial considerations
• Progression of motor impairment
• Progression of non-motor impairment
• Progression of global disability
• Worsening of Hr-QoL
• Progression of surrogate markers
Health-related Quality of Life in MSA(Schrag et al, 2006)
- N = 115 pts. from EMSA-SG NH Study
- Impairment in all EQ-5D and SF-36 domains
- Significant impairments also relative to PD ! (except pain)
- Autonomic dysfunction (COMPASS), motor impairment (UMSARS) and depression (BDI) closely associated with poor Hr-QoL
- CAVE: No change in SF-36, scores in sample of 27 MSA pts. from 4 EMSA-SG centres over 6 mths (Köllensperger et al, 2006)
Trial considerations
• Progression of motor impairment
• Progression of non-motor impairment
• Progression of global disability
• Worsening of Hr-QoL
• Progression of surrogate markers
• Dopamine D2R DA-D2R-Imaging
(IBZM-SPECT,
Raclopride-PET)• Striatal glucose metabolism FDG-PET • Dopamine transporter DAT-SPECT
(beta-CIT, FP-CIT)• Striatal LD metabolism F-DOPA-PET• Activated microglia PK11195-PET• Basal ganglia atrophy MRT, MRV• Putaminal diffusivity DWI (ADCs)• CSF/Plasma Biomarkers
SURROGATE ENDPOINTS IN MSAConsiderations
Completed Interventional Trials
rhGH Trial: Negative- trophic factor support -
Holmberg et al. 2007, Aberg et al. 2000
Study design: Double-blind RCT
Primary outcome: UPDRS (52 weeks)
N 43
Phase: Phase 2
PI: B. Holmberg
Current Status: Published
Study identifier: Not registered
Minocycline (MEMSA): Negative- microglial de-activation -
Stefanova et al. 2007, Dodel et al. 2010
Study design: Double-blind RCT
Primary outcome: UMSARS II (48 weeks)
N 63
Phase: Phase 3
PI: W. H. Oertel
Current Status: Published
Study identifier: NCT00146809
CD11b + Cresylviolet
PK11195-PET
Riluzole (NNIPPS): Negative- anti-glutamatergic efficacy -
Scherfler et al. 2005, Diguet et al. 2005, Bensimon et al., 2009
Study design: Double-blind RCT
Primary outcome: Survival
N 398
Phase: Phase 3
PI: P. N. Leigh
Current Status: Published
Study identifier: NCT00211224
Rasagiline: Negative- neuronal protection -
MSA
MSA+R 2.5
MSA
MSA+R 2.5
Cytochrome c releaseCaspase activation
Opening of MPTP pore
Apoptosis -
-
- -
Study design: Double-blind RCT
Primary outcome: ∆ UMSARS (48 weeks)
N 174
Phase: Phase 2
PI: W. Poewe
Current Status: Completed
Study identifier: NCT00977665Stefanova et al. 2008, Poewe et al. 2012 (Poster 1182)
Mesenchymal Stem Cells - cell replacement -
Lee et al 2012
Study design: Double-blind RCT
Primary outcome: UMSARS (52 weeks)
N 27
Phase: Phase 2
PI: P. H Lee
Current Status: Published
Study identifier: NCT00911365
Intravenous immunoglobulins- Immunomodulation -
Study design: Open label
Primary outcome: Safety
N 9
Phase: Phase 2
PI: P. Novak
Current Status: Published
Study identifier: NCT00750867
Ongoing Interventional Trials
Rifampicin- α-synuclein clearance -
Ubhi et al. 2008
Study design: Double-blind RCT
Primary outcome: ∆ UMSARS (52 weeks)
N 100
Phase: Phase 3
PI: P. Low, S. Gilman, D. Robertson
Current Status: Data analysis
Study identifier: NCT01287221
Fluoxetine- trophic factor restoration -
Study design: Double-blind RCTPrimary outcome:
∆ UMSARS (52 weeks)
N 87Phase: Phase 2PI: O. RascolCurrent Status: Data analysisStudy identifier: NCT01146548
Ubhi et al. 2012
Future MSA TrialsTargets
• Toxic alpha Synuclein species („prion-like“)• Oligodendroglia versus neurons• Oxidative stress (CoQ 2 mutations)• Neuroinflammation
Future MSA TrialsDesign
• Placebo-controlled vs open label• Parallel group vs cross over• Large versus small• Other?
Future MSA TrialsPopulation
• MSA-P• MSA-C• MSA-AF (OH, UGF, both)• Early, mid-stage• Large size (>200)
Future MSA TrialsEndpoints
• Motor • Autonomic• Cognitive• Psychiatric• QoL/pharmacoeconomics
Future MSA TrialsLogistics
• Funds EU (7FP/Horizon 2020), NIH• Academic networks EMSA, US-ADRC, JAMSA• Registries EMSA-R, GLOMSAR
Important: Support by national MSA groups incl. UK MSA Trust, Belgian/Dutch/French/German MSA Societies, US MSA Coalition, US MSA Awareness, US Fight MSA Initiative
Division of NeurobiologyDepartment of Neurology
Medical University Innsbruck